14 August 2024
By Kaye McIntosh
Up to 30,000 women could benefit from linzagolix, a new treatment option for moderate-to-severe symptoms of uterine fibroids, guidance from the National Institute of Health and Care Excellence has recommended.
The gonadotropin-releasing hormone (GnRH) antagonist is a single tablet, taken once a day.